about
Clinical and molecular complexity of breast cancer metastasesGenome-wide association study identifies a common variant in RAD51B associated with male breast cancer risk.Claudin-4 Expression is Associated With Survival in Ovarian Cancer But Not With Chemotherapy Response.RNA quality in frozen breast cancer samples and the influence on gene expression analysis--a comparison of three evaluation methods using microcapillary electrophoresis traces.Tiling array-CGH for the assessment of genomic similarities among synchronous unilateral and bilateral invasive breast cancer tumor pairs.Involvement of Chromatin Remodeling Genes and the Rho GTPases RhoB and CDC42 in Ovarian Clear Cell Carcinoma.High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer.Laser capture microdissection (LCM) and whole genome amplification (WGA) of DNA from normal breast tissue --- optimization for genome wide array analysesMolecular subtyping of serous ovarian tumors reveals multiple connections to intrinsic breast cancer subtypesMolecular classification of familial non-BRCA1/BRCA2 breast cancerThe landscape of candidate driver genes differs between male and female breast cancer.Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial.Sex Steroid Hormone Receptor Expression Affects Ovarian Cancer Survival.Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies N-acetyltransferase-1 (NAT1) as a novel prognostic biomarker.Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implicationsMicroarrays in breast cancer research and clinical practice--the future lies ahead.The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naïve women with N0/N1 primary breast cancer.Molecular profiling of male breast cancer - lost in translation?Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrencesGlobal Transcriptional Changes Following Statin Treatment in Breast Cancer.A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer.Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition.Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.Cyclin E overexpression obstructs infiltrative behavior in breast cancer: a novel role reflected in the growth pattern of medullary breast cancers.Characterization of a novel breast carcinoma xenograft and cell line derived from a BRCA1 germ-line mutation carrier.Genome methylation patterns in male breast cancer - Identification of an epitype with hypermethylation of polycomb target genes.Gene expression modules in primary breast cancers as risk factors for organotropic patterns of first metastatic spread: a case control study.Nuclear HIF1A expression is strongly prognostic in sporadic but not familial male breast cancer.Molecular subtyping of male breast cancer using alternative definitions and its prognostic impact.DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis.An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression.High proliferation is associated with inferior outcome in male breast cancer patients.ERK1/2 inhibition increases antiestrogen treatment efficacy by interfering with hypoxia-induced downregulation of ERalpha: a combination therapy potentially targeting hypoxic and dormant tumor cells.Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial.Characterizing steroid hormone receptor chromatin binding landscapes in male and female breast cancer.Similarities and differences in the characteristics and primary treatment of breast cancer in men and women - a population based study (Sweden).Requirement of apoptotic protease-activating factor-1 for bortezomib-induced apoptosis but not for Fas-mediated apoptosis in human leukemic cells.Combination of the proliferation marker cyclin A, histological grade, and estrogen receptor status in a new variable with high prognostic impact in breast cancer.Gene-Expression Profiles in Hereditary Breast CancerAbstract P3-02-02: Concordance between immunohistochemical and gene-expression based subtyping of early breast cancer using core needle biopsies and surgical specimens - experices from SCAN-B
P50
Q26796326-FB66A116-F8FF-4E53-AA89-961B7DDA8375Q29417050-4CF57DCD-DC7A-4104-921A-D076FC642DD3Q30491616-3E18ADD2-8B31-4768-B8C7-4246B7FAFDF4Q33285410-C4475B39-DE02-4126-A206-E680EE51FC8DQ33350663-342BA770-599B-4840-BC67-3B9CAFD112BBQ33734760-8FCF07E4-8F43-485E-98CB-F4C9A01633F2Q33757555-5C55FB2E-1F91-4289-8D81-779C47ADC3AFQ33850268-FEA22654-71A2-46EE-83FB-00D36D1FFA7EQ34199368-2D57DAA8-F450-4253-B38F-4CF8DD572809Q34807023-745DBB43-77BC-4197-9996-221F97114A36Q35032523-C035C60E-0D63-425F-AFC6-8AAD9900EA0FQ35583876-4C0501A3-899E-47C4-ADA0-CA029B85D695Q36243394-E505B820-5F70-45D6-8FAA-AB569BB56D55Q36393217-C55073C0-B5E5-4292-875D-70C5A0E9079AQ36545146-8BB52D50-D627-4484-BB20-AF36200450E4Q36678745-721DB079-1518-4605-A5C9-76F39D0CF2E8Q36732425-7C3C8DD1-6A87-43FF-B137-D9563D924F07Q38212920-295F9CA6-96FE-452D-A5F4-3CCB722A6DB1Q38394007-0ECA3116-80D4-4031-B578-29997FA36946Q38465041-BB963EE5-5F4A-4A59-9AB1-71A8FA8FAF1FQ39093555-B5182C38-E83C-4272-9A4A-6B213BA94BC8Q39408501-72723AAC-DA86-4CCC-A6FA-0AAAE8C31AEBQ39792989-DD5C4764-B762-458C-B3B4-5EDB37322CD7Q40355366-6149AECF-6CAA-407D-B37C-2FEB2287FB71Q40662259-DAC9BFF1-D466-4CFA-8230-7B53845C3A4DQ41136382-6375A312-AD2D-4BAE-A214-FBA8F2AA0398Q42377416-50393B21-CC8B-4AF6-8BD8-DB10108F566BQ42453016-EB6E4525-F7CF-4B28-82CF-74709FBCE150Q42511904-ACC2C83E-E67B-4FB5-8F24-A21E835CE9F0Q43829640-2BEFA190-FAB7-42EC-A777-87BBEF606B32Q46017879-34E399A7-A911-4BBA-9C81-374A295A3439Q46532481-C02CEB9E-710F-428C-85E5-49BCDA46CF41Q46592752-62F5FF8A-6939-41CC-BA42-A26345C9C69AQ47757066-1E29E8DE-8493-4C79-8A0A-2F314C6413FEQ48112811-40ED6101-F5F9-4F8E-9F44-6A90751E7042Q51427569-65605ED7-E73B-4860-88C8-B8A8312263F8Q53137734-9849571D-41F4-4162-923C-E2BC89E2D00BQ53266957-3CDD0C0E-8AAE-44FB-ABDC-016F54172E20Q57240053-B97C4101-7A38-433A-BEFE-B15308AB24D6Q57517733-4D5417FF-9F4C-41AA-A77B-553CB0715749
P50
description
Zweeds onderzoekster
@nl
hulumtuese
@sq
researcher
@en
ricercatrice
@it
taighdeoir
@ga
հետազոտող
@hy
name
Ingrid Hedenfalk
@ast
Ingrid Hedenfalk
@en
Ingrid Hedenfalk
@es
Ingrid Hedenfalk
@ga
Ingrid Hedenfalk
@nl
Ingrid Hedenfalk
@sl
Ingrid Hedenfalk
@sq
type
label
Ingrid Hedenfalk
@ast
Ingrid Hedenfalk
@en
Ingrid Hedenfalk
@es
Ingrid Hedenfalk
@ga
Ingrid Hedenfalk
@nl
Ingrid Hedenfalk
@sl
Ingrid Hedenfalk
@sq
prefLabel
Ingrid Hedenfalk
@ast
Ingrid Hedenfalk
@en
Ingrid Hedenfalk
@es
Ingrid Hedenfalk
@ga
Ingrid Hedenfalk
@nl
Ingrid Hedenfalk
@sl
Ingrid Hedenfalk
@sq
P106
P108
P21
P214
6547149296288280670006
P27
P31
P496
0000-0002-6840-3397
P735
P7859
viaf-6547149296288280670006